Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02361112
Other study ID # BLTN-Ic
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 2014
Est. completion date December 2016

Study information

Verified date July 2018
Source Jiangsu HengRui Medicine Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib in combination with capecitabine in patients with HER2 positive metastatic breast cancer:

To evaluate the safety and tolerability of pyrotinib, and the maximum tolerated dose (MTD) To determine the dose-limiting toxicity (DLT) To determine the pharmacokinetic profile of Pyrotinib To assess preliminary antitumor activity To determine preliminary regimen dose for phase II study


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date December 2016
Est. primary completion date August 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Aged =18 and =70 years.

- ECOG performance status of 0 to 1.

- Life expectancy of more than 12 weeks.

- At least one measurable lesion exists.(RECIST 1.1)

- Histologically or cytologic confirmed HER2 positive metastatic breast cancer which failed prior therapies.

- No previous treatment of capecitabin during the past 1 year.

- Required laboratory values including following parameters:

ANC: = 1.5 x 109/L Platelet count: = 100 x 109/L Hemoglobin: = 9.0 g/dL Total bilirubin: = 1.5 x upper limit of normal, ULN ALT and AST: = 1.5 x ULN BUN and creatine clearance rate: = 50 mL/min LVEF: = 50% QTcF: < 470 ms

- Signed informed consent.

Exclusion Criteria:

- Subjects with third space fluid that can not be controled by drainage or other methods.

- Steroid treatment for more than 50 days, or in need of long-term use of steroids.

- Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption.

- Less than 4 weeks from the last radiotherapy,chemotherapy,surgery,hermone treatment,target therapy, or less than 6 weeks from the nitrosoureas or mitomycin chemotherapy.

- Subjects with no efficacy during the previous treatment of capecitabine.

- Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry.

- Subjects who can not interrupt the using of the drugs that may cause QT prolongation during study.

- Subjects with intracranial lesions.

- Subjects with bone or skin as the only target lesion

- Treated or treating with HER2 tyrosine kinase inhibitors (TKIs) before study entry.

- Receiving any other antitumor therapy.

- Less than 4 weeks from the last clinical trial.

- Known history of hypersensitivity to pyrotinib?capecitabine or any of its components or metabolites.

- Ongoing infection (determined by investigator).

- History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation.

- Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial.

- Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test.

- Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period.

- Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study. Examples include, but are not limited to,hypertension, severe diabetes, or thyroid disease.

- Alcoholism, smoking (daily = 5 roots) and other bad habits.

- Known history of neurological or psychiatric disease, including epilepsy or dementia.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
pyrotinib combined with capecitabine


Locations

Country Name City State
China Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Jiangsu HengRui Medicine Co., Ltd. Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The maximum-tolerated dose (MTD) will be defined as the maximum dose level at which no more than one subject out of three experiences has a dose-limiting toxicity (DLT) upon completing one treatment cycle. DLT was difined as the cetain AEs which were observed during the first cycle (D1-D21)of treatment. 21 days
Secondary Cmax, Tmax, T1/2, AUCss and R of pyrotinib and capecitabine in combination 12 months
Secondary the number of participants with adverse event 12 months
Secondary preliminary antitumor activity for the regimen, objective response rate 12 months
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2